Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Challenges of selecting frontline therapy in CLL

Jacqueline Barrientos, MD, MS, Feinstein Institute for Medical Research, Manhasset, NY, outlines the challenges associated with choosing the most appropriate therapeutic regimen for the treatment of chronic lymphocytic leukemia (CLL) in a rapidly evolving field. In particular, Dr Barrientos discusses the advantages and disadvantages of BTK inhibitor therapies, such as ibrutinib and acalabrutininb, compared to fixed-duration BCL-2 inhibitor therapy in combination with obinutuzumab. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Jacqueline Barrientos, MD, MS, has received research funding from AstraZeneca, Oncternal, TG therapeutics and Pharmacyclics/Abbvie; and has participated in advisory boards for AstraZeneca, Pharmacyclics/Abbvie, Beigene, Genentech, Gilead and Innate.